Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 12/20 | 0.48 |
| ▸ | TP53 | P04637 | 8/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996808 | 0.88 | MAPT (0.49) | TSHRMAPTTP53RXFP1LMNA | |
| SCHEMBL4996721 | 0.87 | MAPT (0.47) | TSHRMAPTTP53RXFP1LMNA | |
| SCHEMBL4996916 | 0.85 | GFER (0.49) | TSHRMAPTTP53RXFP1LMNA | |
| SCHEMBL4997364 | 0.81 | TSHR (0.46) | TSHRMAPTTP53RXFP1LMNA | |
| SCHEMBL4992104 | 0.81 | TSHR (0.46) | TSHRMAPTTP53RXFP1LMNA | |
| SCHEMBL4995501 | 0.77 | MAPT (0.49) | TSHRMAPTRXFP1LMNAGFER | |
| SCHEMBL5000915 | 0.75 | PIM2 (0.51) | TSHRMAPTRXFP1LMNAGFER | |
| SCHEMBL4991478 | 0.73 | CHEK1 (0.43) | MAPTSMN1; SMN2DHFR | |
| SCHEMBL5003034 | 0.72 | PIM2 (0.48) | TSHRMAPTLMNA | |
| SCHEMBL4987930 | 0.72 | RAD52 (0.42) | MAPTDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | TSHR 2332/4885MAPT 5/4885TP53 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.